Bovine lactoferrin-derived peptides as novel broad-spectrum inhibitors of influenza virus

References

• Dolin R, Reichman RC, Madore HP, Maynard R, Linton PN, Webber-Jones J. A controlled trial of amantadine and rimantadine in the prophylaxis of influenza A infection. N Engl J Med. 1982:307:580–4.
   PubMed Web of Science ®Google Scholar
• Palese P, Shaw ML, Knipe DM, Howley PM (editors). Orthomyxoviridae: the viruses and their replication. In: Fields virology. Philadelphia, PA: Lippincott Williams & Wilkins; 2007.
   Google Scholar
• Belshe RB, Burk B, Newman F, Cerruti RL, Sim IS. Resistance of influenza A virus to amantadine and rimantadine: results of one decade of surveillance. J Infect Dis. 1989:159:430–5.
   PubMed Web of Science ®Google Scholar
• Hayden FG. Antiviral resistance in influenza viruses – implications for management and pandemic response. N Engl J Med. 2006:354:785–8.
   PubMed Web of Science ®Google Scholar
• Kiso M, Mitamura K, Sakai-Tagawa Y, Shiraishi K, Kawakami C, Kimura K, et al.. Resistant influenza A viruses in children treated with oseltamivir: descriptive study. Lancet. 2004;364:759–65.
   PubMed Web of Science ®Google Scholar
• Meijer A, Lackenby A, Hungnes O, Lina B, van-der-Werf S, Schweiger B, et al.. European influenza surveillance scheme Oseltamivir-resistant influenza virus A (H1N1), Europe, 2007–08 season. Emerg Infect Dis. 2009;15:552–60.
   PubMed Web of Science ®Google Scholar
• Dharan NJ, Gubareva LV, Meyer JJ, Okomo-Adhiambo M, McClinton RC, Marshall SA, et al.. Infections with oseltamivir-resistant influenza A(H1N1) virus in the United States. JAMA 2009;30:1034–41.
   Google Scholar
• Wilson IA, Skehel JJ, Wiley DC. Structure of the hemagglutinin membrane glycoprotein of influenza virus at 3 Å resolution. Nature. 1981;289:366–73.
   PubMed Web of Science ®Google Scholar
• Skehel JJ, Wiley DC. Receptor binding and membrane fusion in virus entry: the influenza hemagglutinin. Annu Rev Biochem. 2000;69:531–69.
   PubMed Web of Science ®Google Scholar
• Wiley DC, Skehel JJ. The structure and function of the hemagglutinin membrane glycoprotein of influenza virus. Annu Rev Biochem. 1987;56:365–94.
   PubMed Web of Science ®Google Scholar
• May JT. Microbial contaminants and antimicrobial properties of human milk. Microbiol Sci. 1988;5:42–6.
   PubMedGoogle Scholar
• Levay PF, Viljoen M. Lactoferrin: a general review. Haematologica. 1995;80:252–67.
   PubMed Web of Science ®Google Scholar
• Palma C, Cassone A, Serbousek D, Pearson CA, Djeu JY. Lactoferrin release and interleukin-1, interleukin-6, and tumor necrosis factor production by human polymorphonuclear cells stimulated by various lipopolysaccharides: relationship to growth inhibition of Candida albicans. Infect Immun. 1992;60:4604–11.
   Web of Science ®Google Scholar
• Harmsen MC, Swart PJ, de B’ethune MP, Pawels R, De Clercq E, Th’e TH, et al.. Antiviral effects of plasma and milk proteins: lactoferrin shows a potent activity against both human immunodeficiencyvirus and human cytomegalovirus replication in vitro. J Infect Dis. 1995;172:380–8.
   PubMed Web of Science ®Google Scholar
• Beljaars L, van der Strate BW, Bakker HI, Reker-Smit C, van Loenen-Weemaes AM, Wiegmans FC, et al.. Inhibition of cytomegalovirus infection by lactoferrin in vitro and in vivo. Antivir Res. 2004;63:197–208.
   PubMed Web of Science ®Google Scholar
• Hasegawa K, Motsuchi W, Tanaka S, Dosako S. Inhibition with lactoferrin of in vitro infection with human herpes virus. Jpn J Med Sci Biol. 1994;47:73–85.
   PubMedGoogle Scholar
• Marchetti M, Trybala E, Superti F, Johansson M, Bergström T. Inhibition of herpes simplex virus infection by lactoferrin is dependent on interference with the virus binding to glycosaminoglycans. Virology. 2004;18:405–13.
   Google Scholar
• Marchetti M, Ammendolia MG, Superti F. Glycosaminoglycans are not indispensable for the anti-herpes simplex virus type 2 activity of lactoferrin. Biochimie. 2009;91:155–9.
   Web of Science ®Google Scholar
• Ammendolia MG, Marchetti M, Superti F. Bovine lactoferrin prevents the entry and intercellular spread of herpes simplex virus type 1 in Green Monkey Kidney cells. Antiviral Res. 2007;76:252–62.
   PubMed Web of Science ®Google Scholar
• Yi M, Kaneko S, Yu DY, Murakami S. Hepatitis C virus envelope proteins bind lactoferrin. J Virol. 1997;71:5997–6002.
   PubMed Web of Science ®Google Scholar
• Murphy ME, Kariwa H, Mizutani T, Yoshimatsu K, Arikawa J, Takashima I. In vitro antiviral activity of lactoferrin and ribavirin upon hantavirus. Arch Virol. 2000;145:1571–82.
   PubMed Web of Science ®Google Scholar
• Hara K, Ikeda M, Saito S, Matsumoto S, Numata K, Kato N, et al.. Lactoferrin inhibits hepatitis B virus infection in cultured human hepatocytes. Hepatol Res. 2002;24:228–35.
   PubMed Web of Science ®Google Scholar
• Sano H, Nagai K, Tsutsumi H, Kuroki Y. Lactoferrin and surfactant protein A exhibit distinct binding specificity to F protein and differently modulate respiratory syncytial virus infection. Eur J Immunol. 2003;33:2894–902.
   PubMed Web of Science ®Google Scholar
• Norris GE, Gartner AL, Anderson BF, Ward J, Baker EN, Rumball SV, et al.. Preliminary crystallographic studies on bovine lactoferrin. J Mol Biol. 1986;191:143–5.
   Web of Science ®Google Scholar
• Moore SA, Anderson BF, Groom CR, Haridas M, Baker EN. Three-dimensional structure of diferric bovine lactoferrin at 2.8 °A resolution. J Mol Biol. 1997;274:222–36.
   PubMed Web of Science ®Google Scholar
• Superti F, Ammendolia MG, Valenti P, Seganti L. Antirotaviral activity of milk proteins: lactoferrin prevents rotavirus infection in the enterocyte-like cell line HT-29. Med Microbiol Immunol. 1997;186:83–91.
   PubMed Web of Science ®Google Scholar
• Pietrantoni A, Di Biase AM, Tinari A, Marchetti M, Valenti P, Seganti L, et al.. Bovine lactoferrin inhibits adenovirus infection by interacting with viral structural polypeptides. Antimicrob Agents Chemother. 2003;47:2688–91.
   PubMed Web of Science ®Google Scholar
• Ammendolia MG, Pietrantoni A, Tinari A, Valenti P, Superti F. Bovine lactoferrin inhibits echovirus endocytic pathway by interacting with viral structural polypeptides. Antiviral Res. 2007;73:151–60.
   Web of Science ®Google Scholar
• Pietrantoni A, Dofrelli E, Tinari A, Ammendolia MG, Puzelli S, Fabiani C, et al.. Bovine lactoferrin inhibits influenza A virus induced programmed cell death in vitro. Biometals. 2010;23:465–75.
   Web of Science ®Google Scholar
• Gaush CR, Smith TF. Replication and plaque assay of influenza virus in an established line of canine kidney cells. Appl Microbiol. 1968;16:588–94.
   PubMedGoogle Scholar
• Rimmelzwaan GF, Baars M, Claas EC, Osterhaus AD. Comparison of RNA hybridization, hemagglutination assay, titration of infectious virus and immunofluorescence as methods for monitoring influenza virus replication in vitro. J Virol Methods. 1998;74:57–66.
   PubMed Web of Science ®Google Scholar
• Pietrantoni A, Ammendolia MG, Tinari A, Siciliano R, Valenti P, Superti F. Bovine lactoferrin peptidic fragments involved in inhibition of Echovirus 6 in vitro infection. Antiviral Res. 2006:69:98–106.
   Web of Science ®Google Scholar
• Superti F, Siciliano R, Rega B, Giansanti F, Valenti P, Antonini G. Involvement of bovine lactoferrin metal saturation, sialic acid and protein fragments in the inhibition of rotavirus infection. Biochim Biophys Acta. 2001;1528:107–15.
   PubMed Web of Science ®Google Scholar
• Laemmli UK. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature. 1970;227:680–5.
   PubMed Web of Science ®Google Scholar
• Morris GM, Goodsell DS, Halliday RS, Huey R, William E, Hart WE, et al.. Automated docking using a Lamarckian genetic algorithm and an empirical binding free energy function. J Comput Chem. 1998;19:1639–62.
   Web of Science ®Google Scholar
• Chen R, Weng Z. Docking unbound proteins using shape complementarity, desolvation, and electrostatics. Proteins. 2002;47:281–94.
   PubMed Web of Science ®Google Scholar
• Li L, Chen R, Weng Z. RDOCK: refinement of rigid-body protein docking predictions. Proteins. 2003;53:693–707.
   PubMed Web of Science ®Google Scholar
• Kozakov D, Brenke R, Comeau SR, Vajda S. PIPER: an FFT-based protein docking program with pairwise potentials. Proteins. 2006;65:392–406.
   PubMed Web of Science ®Google Scholar
• Schneidman-Duhovny D, Inbar Y, Nussinov R, Wolfson HJ. PatchDock and SymmDock: servers for rigid and symmetric docking. Nucleic Acids Res. 2005;33(Web Server issue):W363–7.
   Google Scholar
• Andrusier N, Nussinov R, Wolfson HJ. FireDock: fast interaction refinement in molecular docking. Proteins. 2007;69:139–59.
   PubMed Web of Science ®Google Scholar
• Mashiach E, Schneidman-Duhovny D, Andrusier N, Nussinov R, Wolfson HJ. FireDock: a web server for fast interaction refinement in molecular docking. Nucleic Acids Res. 2008;36(Web Server issue):W229–32.
   Google Scholar
• Ekiert DC, Bhabha G, Elsliger MA, Friesen RH, Jongeneelen M, Throsby M, et al.. Antibody recognition of a highly conserved influenza virus epitope. Science. 2009;324:246–51.
   PubMed Web of Science ®Google Scholar
• Kasowski EJ, Garten RJ, Bridges CB. Influenza pandemic epidemiologic and virologic diversity: reminding ourselves of the possibilities. Clin Infect Dis. 2011;52(Suppl 1):S44–9.
   Google Scholar
• Russell RJ, Gamblin SJ, Haire LF, Stevens DJ, Xiao B, Ha Y, et al.. H1 and H7 influenza haemagglutinin structures extend a structural classification of haemagglutinin subtypes. Virology. 2004;325:287–96.
   PubMed Web of Science ®Google Scholar
• Gamblin SJ, Skehel JJ. Influenza hemagglutinin and neuraminidase membrane glycoproteins. J Biol Chem. 2010;285:28403–9.
   PubMed Web of Science ®Google Scholar
• Huang Q, Opitz R, Knapp EW, Herrmann A. Protonation and stability of the globular domain of influenza virus hemagglutinin. Biophys J. 2002;82:1050–8.
   PubMed Web of Science ®Google Scholar
• Mancini N, Solforosi L, Clementi N, De Marco D, Clementi M, Burioni R. A potential role for monoclonal antibodies in prophylactic and therapeutic treatment of influenza. Antiviral Res. 2011;92:15–26.
   PubMed Web of Science ®Google Scholar
• Edwards MJ, Dimmock NJ. Hemagglutinin 1-specific immunoglobulin G and Fab molecules mediate postattachment neutralization of influenza A virus by inhibition of an early fusion event. J Virol. 2001;75:10208–18.
   Web of Science ®Google Scholar
• Sui J, Hwang WC, Perez S, Wei G, Aird D, Chen LM, et al.. Structural and functional bases for broad-spectrum neutralization of avian and human influenza A viruses. Nat Struct Mol Biol. 2009;16:265–73.
   PubMed Web of Science ®Google Scholar
• Corti D, Voss J, Gamblin SJ, Codoni G, Macagno A, Jarrossay D, et al.. A neutralizing antibody selected from plasma cells that binds to group 1 and group 2 influenza A hemagglutinins. Science. 2011;333:850–6.
   PubMed Web of Science ®Google Scholar